Rita Nanda
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 19
- Cancer Immunotherapy and Biomarkers 8
- HER2/EGFR in Cancer Research 6
- CAR-T cell therapy research 3
-
- Advanced Breast Cancer Therapies 7
- Co-authors
- Kumudu Pathiraja (1 shared paper)Jonathan D. Cheng (1 shared paper)Vassiliki Karantza (1 shared paper)Gursel Aktan (1 shared paper)Laura Q.M. Chow (1 shared paper)Raanan Berger (1 shared paper)Laurence Buisseret (1 shared paper)Shilpa Gupta (1 shared paper)
- Journals
- Journal of Clinical Oncology (12 papers)Therapeutic Advances in Medical Oncology (2 papers)Cancer Research (2 papers)Cancer (1 paper)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Rita Nanda
18 papers receiving 1.4k citations
Rita Nanda's Hit Papers
Peers
Comparison fields: 5 of 77
- Oncology 1.2k
- Immunology 507
- Cancer Research 306
- Pulmonary and Respiratory Medicine 401
- Psychiatry and Mental health 72
Countries citing papers authored by Rita Nanda
This map shows the geographic impact of Rita Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Nanda more than expected).
Fields of papers citing papers by Rita Nanda
This network shows the impact of papers produced by Rita Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Nanda. The network helps show where Rita Nanda may publish in the future.
Co-authors
The 25 scholars most cited alongside Rita Nanda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study Hit paper breakdown → | 2016 | 1112 |
| 2 | 2017 | 92 | |
| 3 | 2018 | 73 | |
| 4 | 2013 | 47 | |
| 5 | 2016 | 25 | |
| 6 | 2018 | 24 | |
| 7 | 2021 | 18 | |
| 8 | 2018 | 15 | |
| 9 | 2020 | 15 | |
| 10 | 2021 | 14 | |
| 11 | 2021 | 13 | |
| 12 | 2021 | 6 | |
| 13 | 2024 | 6 | |
| 14 | 2025 | 4 | |
| 15 | 2021 | 4 | |
| 16 | 2021 | 3 | |
| 17 | 2025 | 2 | |
| 18 | 2024 | 1 | |
| 19 | 2024 | 0 | |
| 20 | 2021 | 0 |
About Rita Nanda
Rita Nanda is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 22 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Advanced Breast Cancer Therapies (7 papers), HER2/EGFR in Cancer Research (6 papers), Breast Cancer Treatment Studies (4 papers), CAR-T cell therapy research (3 papers), Pharmacogenetics and Drug Metabolism (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Oncology (1.2k citations), Immunology (507 citations), Cancer Research (306 citations), Pulmonary and Respiratory Medicine (401 citations) and Psychiatry and Mental health (72 citations). Rita Nanda has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Kumudu Pathiraja, Jonathan D. Cheng, Vassiliki Karantza, Gursel Aktan, Laura Q.M. Chow, Raanan Berger, Laurence Buisseret, Shilpa Gupta, Ravit Geva and Lajos Pusztai. Their work appears in journals such as Journal of Clinical Oncology, Therapeutic Advances in Medical Oncology, Cancer Research, Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.